Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab + daratumumab + lenalidomide vs daratumumab + bortezomib + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
CTR20233883Phase 3Active
- Sponsor
- Pfizer
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Started Dec 2025; status: active.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20233883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233883.